|Datasheet||Components||Specific References||Reviews||Related Products|
|Solid Phase Sandwich ELISA|
|For the quantitative determination of Human VEGFR3 / FLT-4 concentration in serum.|
The use of this kit for other sample types need be validated by the end user due to the complexity of natural targets and unpredictable interference.
|The minimum detectable dose of Human VEGFR3 / FLT-4 is typically less than 7.95 pg/mL. The MDD was determined by adding three standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.|
|1. 96 well microplate coated with Capture Antibody|
2. Detection Antibody conjugated to HRP
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
|Unopened Kit: Store at 2 - 8℃|
Opened/Reconstituted Reagents: Please refer to CoA
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.